Stefano Lazzeri1,2, Guido Ripandelli2, Maria Sole Sartini1, Mariacristina Parravano2, Monica Varano2, Marco Nardi1, Teresa Di Desidero3, Paola Orlandi3, Guido Bocci4. 1. Department of Surgical, Medical and Molecular Pathology and of Critical Area. Operative Unit of "University Ophthalmology", University of Pisa, Pisa, Italy. 2. Bietti Foundation, IRCCS, Rome, Italy. 3. Division of Pharmacology, Department of Clinical and Experimental Medicine, University of Pisa, Scuola Medica - Via Roma 55, 56126, Pisa, Italy. 4. Division of Pharmacology, Department of Clinical and Experimental Medicine, University of Pisa, Scuola Medica - Via Roma 55, 56126, Pisa, Italy. guido.bocci@med.unipi.it.
Abstract
PURPOSE: The recent introduction of anti-VEGF drugs has widely changed the prognosis of exudative age-related macular degeneration (AMD), even if a variable percentage of patients showed an insufficient response. Aflibercept is a new anti-VEGF drug approved by FDA for the treatment of exudative AMD with a wider binding capacity than either bevacizumab or ranibizumab. Therefore, the purposes were as follows: (i) to report anatomical and functional outcomes of switching from bevacizumab/ranibizumab to aflibercept previously described in the scientific literature, (ii) to hypothesize the possible pathophysiological mechanisms of the resistance and tachyphylaxis to anti-VEGF drugs, and (iii) to suggest possible clinical actions to increase the chances of success for such difficult cases. METHODS: We reviewed the available scientific literature in Medline, Cochrane database, Current Contents, PubMed, and cross-referencing from identified articles, regarding the treatment of exudative AMD patients refractory to bevacizumab and/or ranibizumab and switched to aflibercept monotherapy. We included in this review all the cases in which the diagnosis of refractory or resistant exudative AMD was properly made, and the results of at least one aflibercept injection were described. FINDINGS: We reported the outcomes of 21 papers for a total of 1066 eyes affected by exudative AMD resistant to previous anti-VEGF drug injections and switched to aflibercept. Enrolled reports were divided into two groups: 5 prospective reports and 16 retrospective reports. All the reported papers conclude their analysis, stating that switching from bevacizumab/ranibizumab to aflibercept injections can improve outcomes successfully in refractory neovascular AMD patients. IMPLICATIONS: Analysis of the papers reported in this review demonstrates that switching from bevacizumab/ranibizumab to aflibercept injections can improve outcomes successfully in refractory neovascular AMD patients. The mechanism for these effects is not yet completely understood.
PURPOSE: The recent introduction of anti-VEGF drugs has widely changed the prognosis of exudative age-related macular degeneration (AMD), even if a variable percentage of patients showed an insufficient response. Aflibercept is a new anti-VEGF drug approved by FDA for the treatment of exudative AMD with a wider binding capacity than either bevacizumab or ranibizumab. Therefore, the purposes were as follows: (i) to report anatomical and functional outcomes of switching from bevacizumab/ranibizumab to aflibercept previously described in the scientific literature, (ii) to hypothesize the possible pathophysiological mechanisms of the resistance and tachyphylaxis to anti-VEGF drugs, and (iii) to suggest possible clinical actions to increase the chances of success for such difficult cases. METHODS: We reviewed the available scientific literature in Medline, Cochrane database, Current Contents, PubMed, and cross-referencing from identified articles, regarding the treatment of exudative AMDpatients refractory to bevacizumab and/or ranibizumab and switched to aflibercept monotherapy. We included in this review all the cases in which the diagnosis of refractory or resistant exudative AMD was properly made, and the results of at least one aflibercept injection were described. FINDINGS: We reported the outcomes of 21 papers for a total of 1066 eyes affected by exudative AMD resistant to previous anti-VEGF drug injections and switched to aflibercept. Enrolled reports were divided into two groups: 5 prospective reports and 16 retrospective reports. All the reported papers conclude their analysis, stating that switching from bevacizumab/ranibizumab to aflibercept injections can improve outcomes successfully in refractory neovascular AMDpatients. IMPLICATIONS: Analysis of the papers reported in this review demonstrates that switching from bevacizumab/ranibizumab to aflibercept injections can improve outcomes successfully in refractory neovascular AMDpatients. The mechanism for these effects is not yet completely understood.
Authors: Cecilia S Lee; Alisa J Kim; Douglas Baughman; Catherine Egan; Clare Bailey; Robert L Johnston; Salim Natha; Rehna Khan; Christopher Brand; Toks Akerele; Martin McKibbin; Louise Downey; Saher Al-Husainy; Aaron Y Lee; Adnan Tufail Journal: Retina Date: 2018-05 Impact factor: 4.256
Authors: L Tiosano; O Segal; N Mathalone; A Pollack; R Ehrlich; I Klemperer; Y Barak; I Moroz; I Chowers; M Goldstein Journal: Eye (Lond) Date: 2017-02-17 Impact factor: 3.775
Authors: Michael Mimouni; Amit Meshi; Igor Vainer; Assaf Gershoni; Tal Koren; Noa Geffen; Arie Y Nemet; Ori Segal Journal: Jpn J Ophthalmol Date: 2018-09-29 Impact factor: 2.447
Authors: Christian Lange; Erik Storkebaum; Carmen Ruiz de Almodóvar; Mieke Dewerchin; Peter Carmeliet Journal: Nat Rev Neurol Date: 2016-07-01 Impact factor: 42.937